 Evelo Biosciences, Inc. EVLO, a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical industry veteran Juan Andres to its Board of Directors. We are pleased to welcome Juan to our Board during an important time in Evelos growth, said David Epstein, Chairman of the Evelo Board of Directors. 